Karyopharm Therapeutics traded at $5.64 this Friday May 27th, decreasing $0.17 or 2.93 percent since the previous trading session. Looking back, over the last four weeks, Karyopharm Therapeutics lost 11.88 percent. Over the last 12 months, its price fell by 39.55 percent. Looking ahead, we forecast Karyopharm Therapeutics to be priced at 5.72 by the end of this quarter and at 5.30 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
5.64
Daily Change
-2.93%
Yearly
-39.55%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,761.00 -1.00 -0.03% -1.29%
AbbVie 150.01 -0.56 -0.37% 32.52%
Abbott 116.63 1.76 1.53% -0.02%
Amgen 255.19 2.14 0.84% 7.25%
Avrobio Inc 0.94 0.04 4.09% -89.44%
AstraZeneca 10,474.00 -72.00 -0.68% 30.18%
Astrazeneca 66.70 0 0% 17.24%
BioCryst Pharmaceuticals 9.84 0.79 8.73% -37.60%
Bristol-Myers Squibb 76.14 -1.45 -1.87% 15.86%
Enanta Pharmaceuticals 38.15 0.02 0.05% -22.94%
Epizyme 0.44 -0.001 -0.20% -94.75%
GlaxoSmithKline 1,738.00 -15.80 -0.90% 29.30%
Incyte Corp 77.17 1.15 1.51% -7.89%
J&J 181.11 1.65 0.92% 7.01%
Karyopharm Therapeutics 5.64 -0.17 -2.93% -39.55%
Eli Lilly 323.51 10.05 3.21% 61.97%
MacroGenics 3.33 -0.10 -2.92% -89.45%
Merck & Co 93.09 0.79 0.86% 22.66%
Mirati Therapeutics 33.62 -24.84 -42.49% -78.02%
Nektar Therapeutics 3.56 0.10 2.89% -80.30%
Novartis 86.92 -0.90 -1.02% 8.66%
Novartis 90.88 -0.38 -0.42% 2.71%
Pfizer 53.89 -0.10 -0.19% 39.14%
Ultragenyx Pharmaceutical 45.93 0.09 0.19% -55.65%
Regeneron Pharmaceuticals 692.57 9.13 1.34% 37.84%
Roche Holding 328.20 -4.80 -1.44% 4.79%
Sangamo BioSciences 3.56 0.02 0.42% -67.20%
TG Therapeutics 5.03 -0.02 -0.40% -85.03%
Xencor 22.45 0.09 0.38% -41.64%

Indexes Price Day Year
USND 12131 390.48 3.33% -11.77%
US2000 1888 49.66 2.70% -16.80%

Karyopharm Therapeutics
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (CRM1). Its lead compound, XPOVIO (selinexor), is marketed in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). NEXPOVIO (selinexor), the brand name for XPOVIO in Europe, in combination with dexamethasone to treat adult patients with multiple myeloma. It is also developing treatments for other diseases.